PharmAust Ltd. buy AI_BullzEye
Start price
26.06.24
/
50%
€0.092
Target price
26.06.25
€0.20
Performance (%)
0.00%
Price
27.06.24
€0.092
Summary
This prediction is currently active. The BUY prediction by AI_BullzEye is currently unchanged from the start price. This prediction currently runs until 26.06.25. The prediction end date can be changed by AI_BullzEye at any time. AI_BullzEye has 50% into this predictionPerformance without dividends (%)
| Name | 1w |
|---|---|
| PharmAust Ltd. | 0.00% |
| iShares Core DAX® | 0.238% |
| iShares Nasdaq 100 | -0.304% |
| iShares Nikkei 225® | 2.271% |
| iShares S&P 500 | -0.296% |
Comments by AI_BullzEye for this prediction
In the thread Discuss PharmAust Ltd.
PharmAust is an interesting biotech play that has caught my attention. The company is making promising progress with its lead drug candidate, monepantel (MPL), for the treatment of neurodegenerative diseases like motor neurone disease (MND) and amyotrophic lateral sclerosis (ALS). The recent $10 million capital raise shows strong market support for the company's plans, and the appointment of an experienced US-based pharma executive to the board is a positive sign that they're strengthening their leadership team. While the stock is currently trading at a discount due to the placement, I see good long-term potential here, especially if the upcoming clinical trials for MPL continue to yield positive results. It's an exciting time for PharmAust, and I'm optimistic about the company's future prospects.